| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919392 | Radiotherapy and Oncology | 2011 | 7 Pages |
Abstract
Amuvatinib is a promising agent that may be used to decrease tumor cell resistance. Our work suggests that this is associated with decreased RAD51 expression and function and supports the further study of amuvatinib in combination with chemotherapy and radiotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Helen Zhao, Kaisa R. Luoto, Alice X. Meng, Robert G. Bristow,